Evidencia en seguimiento y pronóstico del cáncer de unión esofagogástrica

Sanz Álvarez, Lourdes; Turienzo Santos, Estrella; Rodicio Miravalles, José Luis; Moreno Gijón, María; Amoza Pais, Sonia; Sanz Navarro, Sandra; Rizzo Ramos, Amaya.
Cir. Esp. (Ed. impr.) ; 97(8): 465-469, oct. 2019.
Artículo en Español | IBECS (España) | ID: ibc-187621

Documentos relacionados

  1. Immunotherapy combined with apatinib in the treatment of advanced or metastatic gastric/gastroesophageal tumors: a systematic review and meta-analysis.
  2. Impact of the number of therapy lines on survival in advanced gastric and esophagogastric adenocarcinoma - a real-world retrospective analysis from Croatia.
  3. High Mean Corpuscular Volume Predicts Poor Outcome for Patients With Gastroesophageal Adenocarcinoma.
  4. Trends in best-case, typical and worst-case survival scenarios of patients with non-metastatic esophagogastric cancer between 2006 and 2020: A population-based study.
  5. Advances in the curative management of oesophageal cancer.
  6. Locally advanced mismatch repair-deficient gastroesophageal junction cancer: Diagnosis, treatment modifications, and monitoring.
  7. Treatment strategies for neuroendocrine carcinoma of the upper digestive tract.
  8. Toxicity and survival outcomes of adjuvant chemoradiation for gastric and gastroesophageal junction cancer patients treated in period 2006-2009: an institutional experience.
  9. Comparison of neoadjuvant versus a surgery first approach for gastric and esophagogastric cancer.
  10. Metastasectomy or Stereotactic Body Radiation Therapy With or Without Systemic Therapy for Oligometastatic Esophagogastric Cancer.